The FDA is looking into whether hair loss, aspiration and suicidal thoughts may be side effects of GLP-1 receptor agonists, a popular class of weight-loss drugs. The agency on Jan. 2 published a summary of reports received through its Adverse Event Reporting System, or FAERS, saying it is “evaluating the need for regulatory action” after […]
